NeuroXT has won FDA 510(k) clearance for NEXT-Cue, an AI model that reads a brain MRI, a cognitive-test score and basic demographic data to estimate how likely a patient with mild cognitive impairment is to progress to Alzheimer's dementia within five years. The Seoul, South Korea company announced the clearance on 20 October 2026 — its first FDA authorization, and by its own account the start of its US market entry.
NEXT-Cue's clearance, in four figures
Figures from NeuroXT's 20 October 2026 FDA clearance announcement and company background reported by Korea University's technology-transfer office.
Reading MRIs the way a PET scan reads plaque
Most tools that estimate a patient's underlying Alzheimer's pathology rely on positron emission tomography (PET) scans or cerebrospinal-fluid biopsies — accurate, but expensive, invasive or both, and poorly suited to routine screening. NeuroXT's approach, developed out of Korea University research into MRI-based biomarkers, instead trains AI models on standard structural MRI, the scan already ordered for most patients being worked up for cognitive decline. The company's earlier product, NEXT-ATN, applies the same idea to estimate amyloid and tau burden; NEXT-Cue extends it to a forward-looking question — not just what a patient's brain shows today, but how likely they are to decline over the next five years.
Three things NEXT-Cue is betting on
No PET scan needed
By working from a structural MRI already common in a dementia work-up, NEXT-Cue avoids the cost, radiotracer logistics and limited availability that keep amyloid PET out of routine practice.
Three inputs, one score
The software combines brain MRI, a cognitive-assessment score and basic demographic data into a single prognostic estimate, rather than asking clinicians to weigh each input separately.
A five-year window
NEXT-Cue is scoped specifically to patients already diagnosed with MCI, estimating progression risk to Alzheimer's dementia over five years — a narrower, more actionable claim than a general dementia-risk score.
“Receiving FDA 510(k) clearance marks an important milestone in NeuroXT's entry into the U.S. healthcare market.” Joon-Kyung Seong, Chief Executive Officer, NeuroXT — 20 October 2026 announcement
A diagnostics category PET scans still dominate
NEXT-Cue is entering a market still built around imaging and, increasingly, blood draws. The FDA has separately cleared blood-based biomarker tests for amyloid pathology, and competing MRI-based prognostic software already has a toehold: Darmiyan's BrainSee, which estimates five-year progression risk to Alzheimer's dementia from an MRI and cognitive-test scores, received FDA De Novo authorization in January 2024 after an earlier Breakthrough Device designation. NEXT-Cue is not the first MRI-based AI tool FDA has cleared for this exact question — it is the newest entrant into a category Darmiyan effectively opened.
The diagnostics shelf NEXT-Cue is joining
$3.5B → $8B
Global Alzheimer's disease diagnostics market, 2023 to 2030, as estimated by William Blair.
Sources: William Blair, "Tracking the $8 Billion Alzheimer's Disease Diagnostics Market"
Regulatory News outlook
We expect prognostic software like NEXT-Cue to grow as a lower-cost screening layer ahead of PET or blood-biomarker confirmation, rather than displacing either, since NEXT-Cue's own clearance frames it as supplementary information for clinicians, not a standalone diagnosis.
How we got here: William Blair's published range implies roughly 12% annual growth in global Alzheimer's diagnostics spend from 2023 to 2030; we treat MRI-based prognostic software as a small but growing slice of that spend, additive to PET and blood-biomarker testing rather than substitutional, since no payer coverage decision for AI-based MCI prognostic software was identified in this research.
NEXT-Cue against how Alzheimer's risk gets estimated today
| Product | Inputs | Output | US regulatory status |
|---|---|---|---|
| NEXT-Cue (NeuroXT) | Structural MRI, cognitive score, demographics | 5-year MCI-to-Alzheimer's progression estimate | FDA 510(k) cleared, Oct 2026 |
| BrainSee (Darmiyan) | Structural MRI, cognitive test scores | 0-100 score, 5-year progression risk | FDA De Novo authorized, Jan 2024 |
| Amyloid PET imaging | Radiotracer injection, PET scanner | Amyloid plaque burden, present-day | Established, FDA-approved tracers |
| Blood-based pTau217 tests | Blood draw | Amyloid pathology likelihood, present-day | Multiple FDA-cleared assays |
From each company's own labelling, FDA authorization records and public reporting; not a clinical head-to-head comparison. NEXT-Cue and BrainSee both estimate future progression risk; PET and blood tests estimate present-day pathology.
From a Korea University lab to a Seoul startup
NEXT-Cue's road to an FDA clearance
- 2022
NeuroXT founded
Spun out of Korea University research into estimating Alzheimer's-related biomarkers from standard MRI scans, based in Seoul, South Korea.
- 2022–2025
NEXT-ATN developed and marketed in Korea
NeuroXT's earlier product estimates amyloid and tau burden from MRI, building the modeling approach NEXT-Cue later extends to a prognostic question.
- 20 October 2026
FDA 510(k) clearance for NEXT-Cue
NeuroXT wins its first FDA clearance, a Class II authorization for AI software estimating five-year MCI-to-Alzheimer's progression risk.
- Early 2027
Planned Korean commercialization
NeuroXT says it is pursuing MFDS authorization for NEXT-Cue, aiming to launch in its home market.
Why this cleared as a 510(k), not a De Novo
NEXT-Cue reached the market through the FDA's standard 510(k) pathway, which requires showing a device is substantially equivalent to one already legally marketed. That matters here because Darmiyan's BrainSee, which estimates the same five-year MCI-to-Alzheimer's progression risk from MRI and cognitive-test data, took the harder road first: FDA authorized it through the De Novo pathway in January 2024, after an earlier Breakthrough Device designation. A De Novo authorization creates a new device classification and product code where none existed; FDA's own code list now carries a dedicated category for MRI-based MCI prognostic software. NEXT-Cue's simpler 510(k) clearance is the kind of filing that becomes available once a category like that exists — a second mover's regulatory shortcut, not a sign the review was any less rigorous on safety and substantial equivalence grounds.
That sequencing also shapes how RA teams should read the clearance. A 510(k) confirms NEXT-Cue is substantially equivalent to a predicate on the specific grounds FDA reviewed — typically intended use, technological characteristics and performance testing — not that it matches or exceeds that predicate's accuracy. Neither NeuroXT's announcement nor the trade coverage this article reviewed disclosed a head-to-head performance comparison against BrainSee or any other prognostic tool, so clinicians choosing between them today are working from each company's own, separately reviewed claims rather than a shared evidence base.
What the clearance does not yet show: NeuroXT has not published independent, peer-reviewed validation data for NEXT-Cue specifically in any source this article could verify, and no FDA 510(k) database record for the device's K-number had been indexed as of this writing. Nor is it clear how payers will treat a prognostic-only AI tool that does not itself diagnose Alzheimer's disease — a question that will likely do more to determine NEXT-Cue's US uptake than the clearance itself.
Sources & further reading
- NeuroXT Inc., "NeuroXT Inc. Receives U.S. FDA 510(k) Clearance for NEXT-Cue, AI Software Supporting Prognostic Assessment in Mild Cognitive Impairment," press release, 20 October 2026. prnewswire.com
- Diagnostic Imaging, "FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment," October 2026. diagnosticimaging.com
- BioPharma APAC, "NeuroXT Secures US FDA Clearance for AI-Powered Tool Predicting Alzheimer's Dementia Progression," October 2026. biopharmaapac.com
- Korea University Technology Licensing Office, NeuroXT partnership background. tlo.korea.ac.kr
- BioSpace, "MCRA Supports Darmiyan with FDA Approval for BrainSee Device," January 2024. biospace.com
- William Blair, "Tracking the $8 Billion Alzheimer's Disease Diagnostics Market." williamblair.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What does NEXT-Cue actually do?
It is AI-based software as a medical device (SaMD) that combines a patient's brain MRI, cognitive-assessment scores and demographic information to provide clinicians a supplementary estimate of whether a patient already diagnosed with mild cognitive impairment (MCI) is likely to progress to Alzheimer's dementia within five years. It is not a standalone diagnostic and is intended for adjunctive use alongside a clinician's own assessment.
Is this NeuroXT's first FDA clearance?
Yes. The company's CEO described the clearance as marking NeuroXT's entry into the US market. NeuroXT's earlier products, including NEXT-ATN (an amyloid/tau biomarker estimator), were developed and marketed in South Korea; this article found no record of a prior US FDA clearance for the company.
Does FDA clearance mean NEXT-Cue is as accurate as a PET scan or blood test?
FDA clearance confirms the device met the agency's requirements for a Class II prognostic-assessment tool, not that it matches or exceeds any specific alternative. NeuroXT has not published independent, peer-reviewed accuracy data for NEXT-Cue itself in the sources this article could verify; the company's clearance announcement describes its role as supplementary information for clinicians, not a replacement for amyloid PET imaging or blood-based biomarker tests.
Where else is NeuroXT seeking approval?
The company says it is separately pursuing authorization for NEXT-Cue from South Korea's Ministry of Food and Drug Safety (MFDS), with plans to begin commercialization in the Korean market in early 2027.
